Published on 21.02.17 in Vol 5, No 2 (2017): February
Works citing "Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia"
According to Crossref, the following articles are citing this article (DOI 10.2196/mhealth.7030):
(note that this is only a small subset of citations)
- Fiske A, Henningsen P, Buyx A. Your Robot Therapist Will See You Now: Ethical Implications of Embodied Artificial Intelligence in Psychiatry, Psychology, and Psychotherapy. Journal of Medical Internet Research 2019;21(5):e13216CrossRef
- Gandhi M, Bacchetti P, Spinelli MA, Okochi H, Baeten JM, Siriprakaisil O, Klinbuayaem V, Rodrigues WC, Wang G, Vincent M, Cressey TR, Drain PK. Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes 2019;81(1):72CrossRef
- Mak K, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today 2019;24(3):773CrossRef
- Steinkamp JM, Goldblatt N, Borodovsky JT, LaVertu A, Kronish IM, Marsch LA, Schuman-Olivier Z. Technological Interventions for Medication Adherence in Adult Mental Health and Substance Use Disorders: A Systematic Review. JMIR Mental Health 2019;6(3):e12493CrossRef
- Fogel AL, Kvedar JC. Artificial intelligence powers digital medicine. npj Digital Medicine 2018;1(1)CrossRef
- McCaul ME, Wand GS. Detecting Deception in Our Research Participants: Are Your Participants Who You Think They Are?. Alcoholism: Clinical and Experimental Research 2018;42(2):230CrossRef
- Boehme P, Wienand P, Herrmann M, Truebel H, Mondritzki T. New digital adherence devices could prevent millions of strokes from atrial fibrillation by the end of the next century. Medical Hypotheses 2017;108:46CrossRef